Invention Grant
- Patent Title: Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor
-
Application No.: US16827650Application Date: 2020-03-23
-
Publication No.: US10993942B2Publication Date: 2021-05-04
- Inventor: Deepak Sampath , Christian Klein , Wayne John Fairbrother , Sari L. Heitner Enschede , Rod A. Humerickhouse , Andrew W. Roberts , John F. Seymour
- Applicant: GENENTECH, INC. , HOFFMANN-LA ROCHE INC. , ABBVIE INC.
- Applicant Address: US CA South San Francisco; US NJ Little Falls; US IL North Chicago
- Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee: GENENTECH, INC.,HOFFMANN-LA ROCHE INC.,ABBVIE INC.
- Current Assignee Address: US CA South San Francisco; US NJ Little Falls; US IL North Chicago
- Agency: Jones Day
- Main IPC: A61K31/496
- IPC: A61K31/496 ; A61P35/02 ; A61P35/00
Abstract:
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
Public/Granted literature
- US20200253963A1 COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR Public/Granted day:2020-08-13
Information query
IPC分类:
